In The Spotlight
DDNews Cancer Research Exclusive
 
 
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
 
(Photo credit: University of Toronto)
 
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
 
 
NEWS
A roundup of recent research and deal-making news in the field of immuno-oncology, as well as a bonus guest commentary from Novella Clinical
 
New studies indicate a valid, predictive biomarker for mCRPC
 
Apeiron signs licensing deal for new checkpoint inhibitor with the Medical University of Vienna and IMB
 
The agreement is centered on an antibody development program that targets a glycan found in several solid tumors
 
Biodesix acquires Integrated Diagnostics Inc., including its blood-based test designed to improve lung cancer diagnosis
 
USCF team pinpoints how benign moles become cancerous and recreate the process with CRISPR
 
AbbVie and Calibr announce collaboration for next-gen T cell therapies, focused on switchable CAR-T therapies aimed primarily at solid tumors
 
Clinical data highlighting single-cell polyfunctionality as a potential predictor of patient response to CAR-T cell therapy published in journal
 
 
FEATURES
(Photo credit: NCI, NIH)
 
 
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
 
OPINION
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors


 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.